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Comprehensive discovery of genetic mechanisms of
drug resistance and identification of in vivo drug
targets represent significant challenges. Here we
present a functional variomics technology in the
model organism Saccharomyces cerevisiae. This
tool analyzes numerous genetic variants and effec-
tively tackles both problems simultaneously. Using
this tool, we discovered almost all genes that, due
tomutations ormodest overexpression, confer resis-
tance to rapamycin, cycloheximide, and amphoteri-
cin B. Most significant among the resistance genes
were drug targets, including multiple targets of
a given drug. With amphotericin B, we discovered
the highly conserved membrane protein Pmp3 as
a potent resistance factor and a possible target.
Widespread application of this tool should allow
rapid identification of conserved resistance mecha-
nisms and targets of many more compounds. New
genes and alleles that confer resistance to other
stresses can also be discovered. Similar tools in
other systems, such as human cell lines, will also
be useful.
INTRODUCTION
Genetic alterations in pathogens or cancer cells are major
causes of drug resistance, with mutations and overexpression
in drug target(s) or target pathways representing the major
mechanisms. Discovering such resistance genes and mutations
has thus also traditionally been exploited to identify drug targets
(Barnes et al., 1984; Heitman et al., 1991; Ka¨ufer et al., 1983;
Rine et al., 1983). Discovering resistance genes could be done
using the recently emerged genome sequencing (Albert et al.,
2005) or high-throughput complementation (Ho et al., 2009)Cmethods. However, the discovery scope afforded by these
methods is typically limited to the number of resistant isolates
or cell lines being studied. Considering that every drug could
encounter multiple resistance mechanisms and that many indi-
vidual drugs may have multiple targets (Rask-Andersen et al.,
2011; Yildirim et al., 2007), many resistant isolates will have to
be analyzed independently using these methods, and this could
be costly and inconvenient.
Here we describe the systematic construction and screening
of numerous genetic variants of the genes in themodel organism
Saccharomyces cerevisiae. This technology, which we termed
‘‘functional variomics,’’ allows simultaneous unbiased and rapid
identification of almost all genes that confer drug resistance
due to mutations or modest overexpression. This technology
centers on a set of high-complexity random mutagenesis (or
variomic) libraries of 90% yeast genes expressed from low-
copy centromeric plasmids. Screening these libraries as mixed
populations of yeast cells against three test compounds rapidly
identified genes as well as most known resistance factors.
Most significant among these were the drug targets, including
multiple targets of a given drug. Using this tool, we discovered
Pmp3, a small-membrane protein highly conserved in fungi
and plants (Mitsuya et al., 2005; Navarre and Goffeau, 2000;
Wang and Shiozaki, 2006), as a novel amphotericin B (AmB)
resistance factor, revealing an aspect of the mechanism of
action of this commonly used antifungal drug. A Candida
albicans homolog also caused AmB resistance when expressed
in S. cerevisiae, suggesting that there is a conservedmechanism
across species.
RESULTS
Constructing the Variomic Libraries
Each variant allele was expressed largely under control of the
native upstream and downstream regulatory sequences from
a centromeric plasmid, with URA3 as the selection marker (Fig-
ure 1A and Figure S1). The variant alleles were flanked by attB1
and attB2 Gateway recombination sequences to facilitate theirell Reports 3, 577–585, February 21, 2013 ª2013 The Authors 577
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Figure 1. A Summary of the Yeast Variomic
Libraries
(A) The variomic library of YFG (or Your Favorite
Gene) was constructed in a heterozygous diploid
deletion mutant that contains a haploid-spe-
cific reporter can1D::(LEU2-MFA1pr-HIS3). Each
mutant allele (YFG*) is expressed under control of
the endogenous promoter (P) and terminator (T)
from a centromeric (CEN) plasmid. The library can
be converted to haploid MATa cells that lack the
chromosomal wild-type gene.
(B) The diagram of a deletion cassette that con-
tains two unique barcodes (uptag and downtag).
(C) The frequency for isolating rapamycin (Rapa)
resistance alleles from TOR2 variomic libraries
both before and after an1,000-fold amplification.
Results of two independent experiments were
averaged and plotted.
See also Figures S1 and S2 and Table S1.transfer to other vectors (Figure 1A). Each library was directly
constructed in the corresponding heterozygous diploid deletion
mutant that harbored a haploid selection reporter (can1D::LEU2-
MFA1pr-HIS3) (Pan et al., 2004), and variant alleles could be
tested both as heterozygous diploid cells and as haploid MATa
cells in the absence of the chromosomal wild-type gene after
haploid conversion (Huang et al., 2008) (Figures 1A and S1; Table
S1). A small subset of variomic libraries were constructed in
heterozygous diploid deletion mutants of other genes due to
a lack of corresponding deletion mutants (Table S1). The pre-
existing barcodes in each yeast-deletion host strain (Giaever
et al., 2002; Winzeler et al., 1999) also identify the corresponding
variomic library (Figure 1A and 1B). A total of 5,847 variomic
libraries were constructed, the majority (>99%) of which con-
tained >2.0 3 105 independent primary alleles (Table S1). The
relatively high genetic diversity of such a variomic library has
been previously demonstrated, with both singular and multiple
mutations present in certain alleles. Mutations within a library
have probably affected almost all amino acid residues of the en-
coded protein (Huang et al., 2008). However, mutational bias as
a result of founder effects during error-prone PCR cannot be
ruled out. Such variomic libraries have been stably amplified at
least 1,000-fold without a discernible loss in the capacity for
discovering drug-resistance genes and alleles, as demonstrated
with two independent TOR2 variomic libraries (Figure 1C) and
the genome-wide screens discussed below.
Interrogating the Libraries for Drug-Resistance Genes
Typically, only 0.5%–2% of variant alleles of a true drug-
resistance gene would confer resistance phenotypes (data not
shown), we therefore anticipated a need to test a relatively large
number of independent alleles in order to evaluate a gene’s
possible role in drug resistance. We estimated that an average
of 10,000 alleles for each gene would be sufficient and
manageable on a genome-wide scale. To screen for resistance
genes, we assembled and amplified a pool of all available vario-
mic libraries, and converted an aliquot of this pool into haploid578 Cell Reports 3, 577–585, February 21, 2013 ª2013 The AuthorsMATa G418R Ura+ cells after meiosis (Figure S2). For each
drug, we screened 6 3 107 such haploid cells at RIC100 to
rapidly enrich resistant alleles. Cells of all resistant colonies
were harvested as a pool and analyzed with barcode deep
sequencing (Smith et al., 2009) to identify the responsible genes
(Figure S2). With each candidate gene, we subsequently
screened 10,000 alleles from the individual variomic library
for resistant alleles and retested them for resistance phenotypes
to establish a causative relationship (Figure S2).
Identifying Rapamycin- and Cycloheximide-Resistance
Genes and Drug Targets
We first tested the immunosuppressant drug rapamycin, which
forms a complex with the FKBP12 peptidyl-prolyl cis-trans isom-
erase (PPIase) to inhibit Tor kinases (Cardenas and Heitman,
1995; Chiu et al., 1994; Choi et al., 1996; Lorenz and Heitman,
1995; Sabatini et al., 1994). Recessive inactivating mutations in
FKBP12 (encoded by FPR1) and dominant mutations in Tor
(encoded by TOR1 and TOR2) confer high levels of resistance
to rapamycin (Heitman et al., 1991). Similar mutations have
also been shown to cause rapamycin resistance in human cells
and fungal pathogens (Bastidas et al., 2012; Cruz et al., 1999;
Dumont et al., 1995). By screening the variomic libraries against
rapamycin with barcode sequencing (Smith et al., 2009), we
found that FPR1, TOR1, and TOR2 were enriched within the
resistant population (all with p values <1 3 10300) (Figure 2A;
Table S2). We also found that inactivating mutations in NPR1
confers rapamycin resistance (p value < 1 3 10300) (Figure 2A;
data not shown), consistent with a previous report (Schmidt
et al., 1998). Therefore, we were able to simultaneously redis-
cover all four known genes that confer rapamycin resistance
due to mutations. Significantly, three of these four genes
represent the drug’s targets, demonstrating that screening the
variomic libraries can simultaneously and accurately identify
potentially multiple targets of a given drug.
The variomic libraries have also provided an excellent oppor-
tunity for discovering key mutations that are responsible for drug
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Figure 2. Rapamycin (Rapa) and Cyclohexi-
mide-Resistance Genes and Alleles Identi-
fied from Screening the Variomic Libraries
(A) Rapa-resistance genes identified from
screening the variomic libraries. Representations
of each gene in both a drug-resistant and a control
population were compared. For simplicity, only
genes with log2 enrichment ratios of >1.0 were
plotted, with names of validated resistance genes
also provided. The graph was derived from
Table S2.
(B) Rapa-resistant alleles isolated from the TOR2
variomic library. Cells expressing wild-type (WT)
or mutant TOR2 of tthe indicated genotypes from
a centromeric plasmid were grown in the presence
or absence of rapamycin (50 ng/ml) at 30C for
2 days.
(C) Cycloheximide (CHX)-resistance genes iden-
tified from screening the variomic libraries. The
graph was derived from Table S2.
(D) Alleles of RPL28 that confer resistance to CHX.
Cells of a wild-type strain BY4743a/a carrying
plasmids of indicated genotypes were grown in
the presence or absence of CHX at 30C for
3 days. CEN is a centromeric low-copy plasmid
and 2m is a high-copy plasmid.
See also Figure S3 and Tables S2 and S3.resistance, some of which may help to define drug-binding sites
on a target protein. For example, mutations residing within the
FKBP12-rapamycin-binding (FRB) domain of Tor (S1972 of
Tor1, S1975,W2041, and F2049 of Tor2) confer rapamycin resis-
tance (Lorenz and Heitman, 1995). In fact, sequencing analysis
of ten resistant alleles each for TOR1 and TOR2 revealed that
they all contained mutations within the FRB domain, including
most of the known ones (Lorenz and Heitman, 1995) and several
novel mutations (Figure 2B; Table S3). Except for tor2N2036D, all
TOR1 and TOR2 alleles tested were dominant or semidominant
and conferred resistance to rapamycin at >50 ng/ml (Figure S3).
Therefore, screening a variomic library allows facile discovery of
resistance mutations within the drug-binding domain of a target
protein.
We next tested cycloheximide, an inhibitor of protein synthe-
sis that binds to eukaryotic ribosomes (Ka¨ufer et al., 1983;
Schneider-Poetsch et al., 2010). Cycloheximide-resistance
mutations were previously found in the target protein Rpl28
and transcription factors Pdr1 and Pdr3 (Katzmann et al.,
1994; Ka¨ufer et al., 1983; Meyers et al., 1992), which regulate
expression of multidrug-resistance transporters. We identified
all three genes by screening the variomic libraries (all with
p values <13 108 (Figure 2C; Table S2). Mutating another tran-
scription factor, Yap1, also conferred cycloheximide resistance
(p value < 1 3 10300) (Figure 2C). We also explored the
possibility of identifying key mutations on target protein Rpl28
that might confer resistance. A Q38E mutation was previously
shown to cause cycloheximide resistance (Ka¨ufer et al., 1983).
Sequencing 64 cycloheximide-resistance RPL28 alleles re-
vealed that all contained mutations at either Q38 or the adjacent
residue, H39 (Figure 2D). The exclusive identification of muta-
tions at Q38 and H39 of Rpl28 suggests a potential binding
site for cycloheximide in this region of the protein.CIdentifying AmB-Resistance Genes
We next studied the commonly used polyene antifungal drug
AmB,which binds to ergosterol and forms transmembrane pores
on the fungal cell membrane, leading to leakage of cellular
contents and cell death (Bolard, 1986; de Kruijff and Demel,
1974). It was recently suggested that the mechanism of action
by AmB and its analogs might be multifaceted (Baginski and
Czub, 2009; Gray et al., 2012; te Welscher et al., 2008). In
addition, clinical resistance to this drug has been rare, except
that deleting ERG6 was previously shown to confer resistance
in vitro, likely due to reduced levels of ergosterol as the putative
drug target or receptor (Broughton et al., 1991; Jensen-Pergakes
et al., 1998; Kelly et al., 1994; Young et al., 2003).
By screening the variomic libraries, we identified six AmB-
resistance genes (all with p values <1 3 108), including ERG6
and ERG11 of the ergosterol biosynthesis pathway, PMP3,
PDR1, RPS7, and RSM24 (Figure 3A). Identification of ERG6
and ERG11 was expected and is consistent with the model
that membrane ergosterol is required for the toxic effect of
AmB (de Kruijff and Demel, 1974). In contrast, the discovery of
PMP3, which encodes a highly conserved hydrophobic small
membrane protein (of 55 amino acids) involved in regulating
ion homeostasis (Navarre and Goffeau, 2000), was unexpected.
Pmp3 contains two predicted transmembrane helical domains
and is likely mostly embedded in the plasma membrane. We
found that barcodes of pmp3D and bsc2D were the most en-
riched, accounting for 11.23% and 83.85%, respectively, of all
barcodes sequenced in the resistant cell population (Figure 3B).
Both of these barcodes were present in the PMP3 variomic
library, because the host cells were by chance a preexisting
mixture of the pmp3D and bsc2D deletion mutants. We subse-
quently found thatmost alleleswithin thePMP3 variomic libraries
were AmB resistant, likely due to modest overexpression fromell Reports 3, 577–585, February 21, 2013 ª2013 The Authors 579
A B
D
C
Figure 3. AmB-Resistance Genes Identified
from Screening the Variomic Libraries
(A) AmB resistance genes identified from
screening the variomic libraries.
(B) Barcode percentage of verified resistance
genes in the AmB-resistant cell population derived
from screening the variomic libraries.
(C) Overexpression of both S. cerevisiae (S.c.)
and C. albicans (C.a.) PMP3 confer resistance to
AmB. Cells shown in this and the next panel
were grown in the presence or absence of AmB
at 30C for 2 days.
(D) A pmp3D mutation confers hypersensitivity
to AmB.
See also Figure S4 and Table S2.the plasmids. Consistent with this idea, expressing wild-type
PMP3 from the same centromeric vector also conferred AmB
resistance (Figure S4). This explained themassive overrepresen-
tation of PMP3 barcodes in the AmB-resistant cell population
(Figure 3B) and, consequently, possible suppression of enrich-
ment ratios of other AmB-resistance genes (Figure 3A). As ex-
pected, expressing PMP3 from a high copy plasmid conferred
AmB resistance (Figure 3C). Overexpressing a Candida albicans
Pmp3 homolog in S. cerevisiae had a similar effect (Figure 3C),
indicating that this mechanism is conserved across species. It
will be interesting to explore whether PMP3 might play a role in
the rare cases of AmB-resistant isolates of fungal pathogens.
Pmp3 Antagonizes the Action of AmB
Consistent with an active role of Pmp3 in AmB resistance, we
also found that a pmp3D mutant was hypersensitive to the
drug (Figure 3D). Given that Pmp3 is required for salt resistance
(Navarre and Goffeau, 2000) (Figure 4A), we initially thought that
it might regulate the flux of ions through pores formed by the
AmB-ergosterol complex on the membrane. However, overex-
pression of PMP3 did not confer resistance to a high concentra-
tion of NaCl in a wild-type strain, nor did it suppress salt hyper-
sensitivity of two mutants (crz1D and mck1D) (Figure 4A). In
contrast, AmB hypersensitivity of both mutants was suppressed
by PMP3 overexpression (Figure 4A). In addition, a sky1Dmuta-
tion that suppresses the salt sensitivity of a pmp3Dmutant (Erez
and Kahana, 2002) failed to suppress its hypersensitivity to
AmB (data not shown). These results together suggest that the
role of PMP3 in AmB-resistance does not involve its role in ion
homeostasis.
We next tested the possibility that Pmp3 directly antagonizes
AmB’s known membrane-permeating effect (de Kruijff and
Demel, 1974). When treated with AmB at R1.0 mg/ml in liquid
cultures, wild-type yeast cells were mostly dead, as reflected
by Sytox uptake and staining (Figure 4B; data not shown). At
an AmB concentration of 1.0 mg/ml, Sytox uptake mainly reflects
membrane permeation, because the antifungal effect of the
drug under this condition is mediated by membrane permeation
rather than other mechanisms, such as ergosterol binding (Gray
et al., 2012). In contrast, cells overexpressing PMP3 were resis-
tant tomembrane permeation under similar conditions, andmost580 Cell Reports 3, 577–585, February 21, 2013 ª2013 The Authorsof them were alive (Figure 4B; data not shown). Therefore,
Pmp3 counteracts the membrane-permeation effect of AmB.
We subsequently investigated whether Pmp3 makes the plasma
membrane more refractory to general chemical perturbations or
specifically to the action(s) of AmB. In support of the latter possi-
bility, PMP3 overexpression had no effect on the membrane-
permeating activity of nystatin (Figure 4B), a structural analog
of AmB. Consistently, PMP3 overexpression failed to confer
resistance to nystatin (Figure 4C) and two other AmB analogs,
filipin and natamycin (Figure 4C). A pmp3D mutation also did
not confer hypersensitivity to these AmB analogs (data not
shown). The specificity in Pmp30s effect toward AmB was also
demonstrated in comparison with erg6D, which confers resis-
tance to AmB and all three AmB analogs in both membrane-
permeation and cell-growth assays (Figures 4B and 4C).
Pmp3 Is a Possible Target of AmB
To further investigate the relationship between Pmp3 and AmB,
we compared the effects of Pmp3 and ergosterol synthesis on
the toxicity of AmB. PMP3 overexpression and erg6D were two
genetic factors that, among all factors tested, confer the highest
levels of AmB resistance (data not shown). We found that PMP3
overexpression confers much higher levels of AmB resistance
even compared to erg6D, and there was little additive effect
between these two (Figure 5A). We also found that pmp3D partly
suppressed AmB resistance conferred by erg6D (Figure 5B).
These results together suggested that Pmp3 likely antagonizes
AmB in a manner that is independent of ergosterol synthesis or
functions. The fact that among all factors tested PMP3 over-
expression confers the highest levels of AmB resistance also
suggests that its effects on AmB resistance are probably not
mediated by other genes. These results, together with the obser-
vation that Pmp3 specifically antagonizes the effect of AmB but
not those of its structural analogs (Figures 4B and 4C) suggest
that Pmp3 might bind directly to AmB. A prediction of this model
is that AmB might also inhibit certain functions of Pmp3. To test
this possibility, we took advantage of synthetically lethal or sick
interactions between pmp3D and mutations affecting actin
polarization (arc18D and vrp1D) (Costanzo et al., 2010) (Fig-
ure 5C) and found that both the arc18D and vrp1D mutants are
hypersensitive to AmB (Figure 5D). Based on these genetic
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Figure 4. Pmp3 Specifically Antagonizes AmB but Not Its Analogs
(A) PMP3 overexpression confers resistance to AmB but not to high salt.
Isogenic strains of indicated genotypes were grown in the presence or
absence of AmB or NaCl at 30C for 2 (DMSO) or 3 days (NaCl and AmB). Note
that growth of the wild-type (WT) strain was similarly impaired, although not
completely blocked, by NaCl in both the presence and absence of PMP3
overexpression.
(B) PMP3 overexpression specifically antagonizes the effect of AmB
(6.0 mg/ml), but not that of nystatin (6.0 mg/ml), on Sytox uptake. An erg6D
mutant was used as a control here and in (C). The result under each condition
was the average of two independent experiments, and the error bar represents
the standard error of the mean. The percentages of permeated cells under all
conditions were: 4.43 ± 0.63 (WT, DMSO); 3.60 ± 0.95 (PMP3, DMSO); 11.55 ±
2.45 (erg6D, DMSO); 98.60 ± 0.60 (WT, AmB); 23.35 ± 0.73 (PMP3, AmB);
16.14 ± 1.55 (erg6D, AmB); 61.47 ± 7.52 (WT, nystatin); 65.45 ± 3.78 (PMP3,
nystatin); 26.90 ± 8.90 (erg6D, nystatin).
(C) PMP3 overexpression confers resistance specifically to AmB but not
nystatin, filipin, and natamycin. Cells were grown at 30C for 3 days.results, we speculate that Pmp3 might be a target of AmB in
yeast.
Taken together, there is likely a bidirectional relationship
between Pmp3 and AmB. In one direction, Pmp3 directly antag-
onizes the membrane-permeation effect of AmB, likely in an
ergosterol-independent manner. It likely also antagonizes the
erogsterol-binding effect of this drug, given that PMP3 overex-
pression has prevented cell death at AmB concentrations that
are much higher than needed for killing through the ergosterol-
binding mechanism (Figure 5A) (Gray et al., 2012). In the other
direction, AmB might inhibit Pmp3. However, it is also possible
that Pmp3 acts simply by preventing insertion of AmB into the
plasma membrane. Such possibilities will need to be further
investigated using biochemical or biophysical assays.CDISCUSSION
Here we describe a powerful functional variomics tool in the
yeast S. cerevisiae for systematic discovery of drug-resistance
genes and alleles and drug targets. This tool shares some simi-
larity with a previously described genome-sequencing approach
(Albert et al., 2005; Wacker et al., 2012) but offers several advan-
tages. First, it is more comprehensive, with most, if not all, genes
of a genome being simultaneously evaluated without bias. As
a result, it discovers multiple resistance genes to a drug simulta-
neously and, consequently, enables simultaneous identification
of potentially multiple targets of a given drug (e.g., Tor1, Tor2,
and FKBP12 for rapamycin). In contrast, the scope of discovery
afforded by the sequencing approach is limited to the particular
mutations harbored within typically a few drug-resistant cell lines
or isolates being sequenced. Even if a large number of such cell
lines or isolates are sequenced regardless of the experimental
cost, there is still a possible ‘‘hot-spot’’ issue, where the same
gene(s) are discovered over and over again while others are
completely overlooked. Second, the presence of numerous
preconstructed variant alleles within the variomic libraries makes
it much easier to obtain drug-resistant isolates for subsequent
gene identification with this tool than with genome sequencing,
which typically relies on spontaneous mutations that occur
at much lower mutational rates. In many cases, even isolat-
ing drug-resistant cell lines is a significant challenge with the
sequencing approach. As a result, functional variomics has
the potential to provide much higher experimental throughput
because many different drugs can be simultaneously screened
with the same preconstructed libraries. In fact, all three screens
described in this study were performed in parallel. Third,
identifying drug-resistance genes with quantitative barcode
sequencing analysis (in the context of functional variomics) is
much simpler than discovering single base substitutions within
a whole genome with the sequencing approach. The huge
potential in sample multiplexing with barcode sequencing anal-
ysis (Smith et al., 2009) could also dramatically reduce the exper-
imental costs with the functional variomics approach. Fourth, the
preconstructed variomic library of a target gene permits conve-
nient isolation of many distinct resistant alleles that could help to
define amino acid residues critical for drug binding or regulation
of the target’s activity. On the other hand, the functional vario-
mics technology does have limitations. It is not applicable in
organisms that do not have convenient genetic tools and does
not allow discovery of resistance mechanisms that involve
multiple genes simultaneously. However, we are optimistic that
a similar tool could be applicable in human cell-culture systems,
where other high-throughput functional genomic tools have
already been successfully implemented.
With the three drugs studied, this functional variomics tool
is also advantageous compared to other existing tools, such
as genome-wide haploinsufficiency profiling (Giaever et al.,
1999) and dosage-suppression screens (Butcher et al., 2006),
in identifying targets. We rediscovered all known or expected
targets or target pathways of the three drugs, including Tor1,
Tor2, FKBP12 of rapamycin, Rpl28 of cycloheximide, and Erg6
and Erg11 of AmB. We also discovered Pmp3 as a possible
target of AmB by taking advantage of potentially modest geneell Reports 3, 577–585, February 21, 2013 ª2013 The Authors 581
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Figure 5. Pmp3 Is a Possible Target of AmB
(A) Different effects ofPMP3 overexpression and erg6D on high levels of AmB resistance. Cells were grown in the presence or absence of AmB at 30C for 3 days.
(B) A pmp3D mutation partly abrogates AmB-resistance conferred by erg6D. Cells were incubated at 30C for 2 days.
(C) The arc18D and vrp1D mutations are synthetically lethal or sick with a pmp3D mutation, as revealed by tetrad analysis.
(D) The arc18D and vrp1D mutations are hypersensitive to AmB. Cells of isogenic strains of indicated genotypes were incubated in the presence or absence of
AmB at 30C for 3 days.overexpression associated with the variomic libraries. In com-
parison, haploinsufficiency profiling would have been successful
with only Tor1 and Tor2, and dosage suppression would have
been successful with Tor1, Tor2, and Pmp3 based on individually
testing all target genes (data not shown). Both methods would
have failed to identify FKBP12, Rpl28, Erg6, and Erg11.
However, mutating a drug target might not always confer drug
resistance. For example, mutations in a target protein that
would have prevented drug binding, and thus caused drug resis-
tance, might also inactivate the protein. In such a case, haploin-
sufficiency profiling and dosage suppression could be more
successful.
In this study, we deliberately chose drug concentrations at or
slightly higher than IC100 in order to rapidly enrich resistant colo-
nies. This has allowed discovery of most of the significant resis-
tance genes and alleles but might have precluded discovery of
those withmarginal effects. Regarding drug-target identification,
there is a tendency or maybe a need to further narrow down the
drug-resistance gene list, possibly by using an even higher drug
concentration in the initial screen. However, as with any positive-
selection screen, resistant colonies could arise from sponta-
neous mutations that are not necessarily associated with the
barcoded genes, and these could lead to false-positive discov-
eries. Depending on the particular genes affected by such spon-
taneous mutations, these false-positive discoveries may or may
not persist when a higher drug concentration is used in the
screen. In addition, as discussedwithPMP3 andBSC2, preexist-
ing cross-contamination of strains used to host the libraries could
also contribute to false-positive discoveries. Given these consid-
erations, we prefer using IC100 of a drug in an initial screen and
subsequently validating the hits with higher drug concentrations
both to weed out false positives and to further distinguish resis-582 Cell Reports 3, 577–585, February 21, 2013 ª2013 The Authorstance levels among the true resistance genes and alleles. This
will allow discovery of most of the drug resistance genes, which
may ormay not confer the same level of drug resistance, allowing
the identification of possibly multiple targets of a given drug.
Here we mainly focused on the application of the functional
variomics tool in systematic and rapid discovery of drug-resis-
tance genes and drug targets. This technology can also be
used to rapidly identify genes and alleles that confer resistance
to other types of stresses such as high temperature, high salt,
high levels of ethanol, and extreme pH. The variant alleles could
also be combined with en masse mating to create strains with
novel phenotypes. In addition, the individual variomic libraries
could be screened to identify conditional or hypomorphic alleles
for studying gene functions. That said, this yeast functional var-
iomics tool is a very valuable resource to the research commu-
nity. Such tools in other genetically tractable organisms (e.g.,
cultured mammalian cells) could also be implemented and will
be similarly useful.
EXPERIMENTAL PROCEDURES
Strains and Plasmids
Yeast strains used in this study include the wild-type diploid strain
BY4743a/a (MATa/a ura3D0/ura3D0 leu2D0/leu2D0 his3D1/his3D1 lys2D0/
LYS2 met15D0/MET15) (Brachmann et al., 1998) and genome-wide haploid
convertible heterozygous diploid yeast deletion mutants (MATa/a ura3D0/
ura3D0 leu2D0/leu2D0 his3D1/his3D1 lys2D0/LYS2 met15D0/MET15 can1D::
LEU2-MFA1pr::HIS3/CAN1 YFG/yfgD::KanMX [where ‘‘YFG’’ stands for Your
Favorite Gene]) (Pan et al., 2006). Bacterial strain DH5a was used as the
host for constructing the promoter/terminator clones and for recovering
plasmids from yeast cells.
The variomic libraries were built on a yeast-bacteria shuttle vector pXP597
or pXP688, both derived from the centromeric plasmid pRS416 (Brachmann
et al., 1998), with URA3 as the selectable marker in yeast. Both vectors
contained a single SmaI site flanked by the Gateway recombination attB1 and
attB2 sites (Figure S1). Their DNA sequences are available upon request. They
are essentially the same, except that the latter contains an additional 22 bp
sequence between the attB1 and attB2 sites to allow more efficient cloning
using homology-dependent methods. All plasmid-borne variant alleles used
in the validation assays were derived from screening the corresponding vario-
mic libraries. The overexpression clones were constructed on a 2 m high-copy
plasmid, pXP684, derived from YEplac195 (Gietz and Sugino, 1988), with each
gene expressed under control of the endogenous promoter and terminator
sequences. A PMP3 homolog from Candida albicans was reverse-translated
using optimal codons of S. cerevisiae, synthesized with overlapping PCR,
and expressed under control of the 50- and 30-UTRs of the S. cerevisiae
PMP3 from pXP684. The DNA sequences of these constructs are also avail-
able upon request.
Chemicals
Rapamycin, cycloheximide, amphotericin B, nystatin, filipin, and natamycin
were all purchased from Sigma. Rapamycin was dissolved in water as a
1 mg/ml stock. All others were dissolved in DMSO as 10 mg/ml stocks. Stock
solutions of Amphotericin B and its analogs were always made and used fresh.
High-Throughput Screening for Resistance Genes
Approximately 6.0 3 107 haploid MATa G418R Ura+ cells derived from the
pooled variomic libraries were plated on a 150 mm plate of solid synthetic
complete medium lacking uracil (SC-Ura) that either contained or lacked
a test compound at RIC100, with an average of 10,000 cells representing
each variomic library. The compounds tested were cycloheximide (at
100 ng/ml), rapamycin (at 20 ng/ml), and amphotericin B (at 4.0 mg/ml). The
plates were incubated at 30C for 3 or 4 days, until the resistant colonies
appeared. Rapamycin-resistant clones were pooled and subjected to an addi-
tional round of selection to clear the relatively high background levels. Resis-
tant clones of the other screens were pooled and directly analyzed by barcode
sequencing as previously reported (Smith et al., 2009). Within each sample, the
numbers of barcode sequences read for both uptag and downtag of each host
strain were averaged and normalized according to a total of one million reads
per sample. Fold enrichment of each host strain in the drug resistance was
calculated by comparing the normalized barcode count against that in a control
population. A differential p value was calculated for each strain between the
drug treatment and control populations based on the Poisson test, which is
widely used on sequencing data (Chen et al., 2012; Zhang et al., 2008). The
p values were further corrected based on the Bonferroni method (Benjamini
and Hochberg, 1995; Benjamini and Yekutieli, 2001). The results of all screens
were presented in Table S2. Genes with enrichment log2 ratios >1.0 and
a p value <1 3 108 were individually retested.
Validating Drug-Resistance Genes and Alleles
To validate a candidate resistance gene, resistant alleles were reisolated from
the corresponding variomic library by screening10,000 freshly derivedMATa
G418R Ura+ cells. Plasmid DNA of each allele was recovered from yeast cells
and transformed into competent DH5a cells. Each recovered plasmid was
transformed back into the corresponding haploid-convertible heterozygous
diploid yeast knockout mutant or a wild-type yeast BY4743a/a by selecting
on solid SC-Ura. Transformants of the heterozygous diploid knockout mutants
were sporulated and converted to haploidMATa G418R Ura+ cells by growing
on SC-Ura-Leu-His-Arg + Canavanine + G418 as previously described (Huang
et al., 2008). Representative haploid isolates were tested for growth on solid
SC-Ura either with or without a drug of interest. Both an empty vector and
a plasmid expressing the corresponding wild-type gene from a centromeric
plasmid were used as negative controls in all cases. The cultures were incu-
bated at 30C for 2 to 3 days and photographed. To test whether the drug-
resistant alleles are dominant or recessive, transformants of BY4743a/a
were spotted as 103 serial dilutions on the surface of SC-Ura plates that either
contained or lacked a drug of interest.
Sytox Uptake Assay
Cells of wild-type yeast BY4743a/a containing a vector (pXP684) or a PMP3
overexpression plasmid and an isogenic erg6D/erg6D mutant containing theCvector were each grown in 5 ml of liquid SC-Ura and incubated at 30C
overnight. Each overnight culture was used to inoculate 5 ml of fresh SC-Ura
at a starting cell density of 0.4 OD600nm/ml, which was incubated at 30
C
for 2 hr. AmB or Nystatin was added at a final concentration of 0 mg/ml,
1.0mg/ml, or 6.0 mg/ml. 5 mM of MgCl2 and 0.2 mM of Sytox Green (Invitrogen)
were also added to each culture, which was incubated at 30Cwith shaking for
6 hr. Cells were observed under an Axioplan 2 imaging microscope and photo-
graphed under both DIC and fluorescence settings. Fluorescence staining of
DNA within a cell indicates uptake of Sytox green and permeation of the
plasma membrane. More than 100 cells were analyzed with each sample,
with the percentage of fluorescence staining cells calculated. Each experiment
was carried out as two independent repeats and the results were averaged and
plotted.
See Extended Experimental Procedures for more details.ACCESSION NUMBERS
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